IntelGenx Technologies (IGXT) 10-K 25 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Jun. 30, 2020
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Entity Registrant Name	IntelGenx Technologies Corp.
Entity Central Index Key	0001098880
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	111,909,533
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Public Float		$ 20,920,883
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Interactive Data Current	Yes

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current
Cash	$ 1,205	$ 1,332
Short-term investments	1,038	580
Accounts receivable	260	381
Prepaid expenses	162	170
Investment tax credits receivable	635	375
Contract asset	354	0
Security deposits	407
Inventory	244	382
Total current assets	4,305	3,220
Leasehold improvements and equipment, net	5,851	6,365
Security deposits	252	752
Operating lease right-of-use-asset	710	683
Total assets	11,118	11,020
Current
Accounts payable and accrued liabilities	1,989	1,941
Current portion of long-term debt	561	727
Current portion of operating lease liability	141	137
Current portion of finance lease liability	25
Deferred revenue	166
Convertible debentures		5,642
Convertible notes	1,486
Total current liabilities	4,368	8,447
Long-term debt	171	470
Convertible notes	1,505	1,255
Convertible debentures	5,461	0
Operating lease liability	482	555
Finance lease liability	84
Total liabilities	12,071	10,727
Commitments
Subsequent event
Shareholders' deficit
Capital stock, common shares, $0.00001 par value; 200,000,000 shares authorized; 111,429,532 shares issued and outstanding (2019: 93,942,652 common shares)	1	1
Additional paid-in capital	48,453	42,635
Accumulated deficit	(48,551)	(41,507)
Accumulated other comprehensive loss	(856)	(836)
Total shareholders' deficit	(953)	293
Total liabilities and shareholders' equity	$ 11,118	$ 11,020

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value per share (in dollars per share)	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	111,429,532	93,942,652
Common Stock, Shares, Outstanding	111,429,532	93,942,652

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning Balance at Dec. 31, 2018	$ 1	$ 42,048	$ (30,896)	$ (1,166)	$ 9,987
Beginning Balance (in shares) at Dec. 31, 2018	93,477,473
Modified retrospective adjustment upon adoption of ASC 842			49		49
Other comprehensive loss (income)				330	330
Interest paid by issuance of common shares		233			233
Interest paid by issuance of common shares (in shares)	415,179
Options exercised		21			21
Options exercised (in shares)	50,000
Stock-based compensation		333			333
Net loss for the year			(10,660)		(10,660)
Ending Balance at Dec. 31, 2019	$ 1	42,635	(41,507)	(836)	293
Ending Balance (in shares) at Dec. 31, 2019	93,942,652
Other comprehensive loss (income)				(20)	(20)
Common stock issued, net of transaction costs of $778		3,912			3,912
Common stock issued, net of transaction costs of $778 (Shares)	16,317,000
Warrants issued, net of transaction costs of $240		1,207			1,207
Agents' warrants issued		169			169
Conversion of convertible debentures		103			103
Conversion of convertible debentures (in shares)	282,000
Interest paid by issuance of common shares		234			234
Interest paid by issuance of common shares (in shares)	887,880
Stock-based compensation		193			193
Net loss for the year			(7,044)		(7,044)
Ending Balance at Dec. 31, 2020	$ 1	$ 48,453	$ (48,551)	$ (856)	$ (953)
Ending Balance (in shares) at Dec. 31, 2020	111,429,532

Consolidated Statement of Sha_2

Consolidated Statement of Shareholders' Equity (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Statement of Stockholders' Equity [Abstract]
Common stock transaction cost	$ 778
Warrants transaction cost	$ 240

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues
Revenues	$ 1,544	$ 742
Total revenues	1,544	742
Expenses
Research and Development Expense	2,637	3,774
Selling, general and administrative expense	4,437	5,800
Depreciation of tangible assets	734	718
Total expenses	7,808	10,292
Operating loss	(6,264)	(9,550)
Interest income	422	97
Financing and interest expense	(1,202)	(1,207)
Net financing and interest expense	(780)	(1,110)
Loss before income taxes	(7,044)	(10,660)
Income taxes	0	0
Net loss	(7,044)	(10,660)
Other comprehensive (loss) income
Change in fair value	102	46
Foreign currency translation adjustment	(122)	284
Total other comprehensive income (loss)	(20)	330
Comprehensive loss	$ (7,064)	$ (10,330)
Basic and diluted:
Weighted average number of shares outstanding (in shares)	108,440,888	93,525,413
Basic and diluted loss per common share (in dollars per share)	$ (0.07)	$ (0.11)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Funds (used) provided - Operating activities
Net loss	$ (7,044)	$ (10,660)
Depreciation of tangible assets	734	718
Stock-based compensation	193	333
Accretion expense	539	514
DSU expense	(142)	105
Interest paid by issuance of common shares	234	228
Gain on debt extinguishment	(401)
Lease non-cash expense	(5)	8
Total Adjustment	(5,892)	(8,754)
Changes in non-cash items related to operations:
Accounts receivable	121	426
Prepaid expenses	8	292
Investment tax credits receivable	(260)	41
Contract asset	(354)
Inventory	138
Security deposits	113
Accounts payable and accrued liabilities	192	(204)
Deferred revenues	166
Net change in non-cash items related to operations	124	555
Net cash used in operating activities	(5,768)	(8,199)
Financing activities
Repayment of long-term debt	(474)	(711)
Proceeds from exercise of warrants and stock options		21
Net proceeds from public offering	5,564
Transaction costs of public offering	(320)
Net proceeds from convertible notes	1,601
Transaction costs of convertible notes	(62)
Transaction costs of debt extinguishment	(69)
Net cash provided by (used in) financing activities	6,240	(690)
Investing activities
Additions to leasehold improvements and equipment	(120)	(525)
Acquisitions of short-term investments	(4,532)	(1,535)
Redemptions of short-term investments	4,126	5,265
Net cash (used in) provided by investing activities	(526)	3,205
Decrease in cash	(54)	(5,684)
Effect of foreign exchange on cash	(73)	201
Cash
Beginning of year	1,332	6,815
End of year	$ 1,205	$ 1,332

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation [Text Block]	1. Basis of Presentation IntelGenx Technologies Corp. (and collectively with IntelGenx Corp., our wholly-owned Canadian subsidiary, “IntelGenx” or the “Company”) prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“USA”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated. The financial statements are expressed in U.S. funds.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2020
Going Concern [Abstract]
Going Concern [Text Block]	2. Going Concern The Company has financed its operations to date primarily through public offerings of its common stock, bank loans, royalty, up-front and milestone payments, license fees, proceeds from exercise of warrants and options, research and development revenues and the sale of U.S. royalty on future sales of Forfivo XL ® On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus ("COVID-19") as a global pandemic, which continues to spread throughout Canada and around the world. The Company is aware of the impact on its business as a result of COVID-19 but uncertain as to the extent of this impact on its consolidated financial statements. The Company has received the Canada Emergency Wage Subsidy and has benefited from the Canada Emergency Commercial Rent Assistance program from its landlord. There is uncertainty as to the duration and hence the potential impact. As a result, we are unable to estimate the potential impact on our business as of the date of this filing. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans to alleviate these conditions include pursuing one or more of the following steps to raise additional funding, none of which can be guaranteed or are entirely within the Company's control: • Raise funding through the possible sale of the common stock, including public or private equity financings. • Raise funding through debt financing. • Continue to seek partners to advance product pipeline. • Initiate oral film manufacturing activities. • Initiate contract oral film manufacturing activities. If the Company is unable to raise further capital when needed or on attractive terms, or if it is unable to procure partnership arrangements to advance its programs, The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The accompanying consolidated financial statements do not include any adjustments or classifications that may result from the possible inability of the Company to continue as a going concern. Should the Company be unable to continue as a going concern, it may be unable to realize the carrying value of its assets and to meet its liabilities as they become due.

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2020
Nature of Business [Abstract]
Nature of Business [Text Block]	3. Nature of Business IntelGenx was incorporated in the State of Delaware as Big Flash Corp. on July 27, 1999. On April 28, 2006 Big Flash Corp. completed, through the Canadian holding corporation, the acquisition of IntelGenx Corp., a company incorporated in Canada on June 15, 2003 and headquartered in Montreal, Quebec. IntelGenx Corp. has continued operations as our operating subsidiary. IntelGenx Corp. is a drug delivery company focused on the development and manufacturing of novel oral thin film products for the pharmaceutical market. More recently, the Company has made the strategic decision to enter the Canadian cannabis market with a non-prescription cannabis infused oral film and in 2020 we made the decision to enter the psychedelic market. The Company's main product development efforts are based upon three delivery platform technologies: (1) VersaFilm™, an oral film technology, (2) AdVersa®, a mucoadhesive tablet technology and (3) the VetaFilm TM The Company's opportunity assessment and product development strategies primarily focus on addressing unmet market needs and utilize the U.S. Food and Drug Administration's ("FDA") 505(b)(2) approval process to obtain more timely and efficient approval of new formulations of previously approved products. The Company's primary growth strategy is based on three pillars: (1) out licensing commercial rights of existing pipeline products, (2) partnering in contract development and manufacturing projects leveraging its various technology platforms, and (3) expanding its current pipeline. The Company's product pipeline currently consists of 11 products in various stages of development from inception through commercialization, including products for the treatment of Alzheimer's disease, opioid dependence, erectile dysfunction, migraine, schizophrenia, idiopathic pulmonary fibrosis, and pain management. Of the products currently under development, 10 utilize the VersaFilm™ VetaFilm™

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies [Text Block]	4. Summary of Significant Accounting Policies Adoption of New Accounting Policies In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments - Credit Losses (Topic 326). The ASU introduces a new credit loss methodology, Current Expected Credit Losses ("CECL"), which requires earlier recognition of credit losses, while also providing additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The CECL methodology utilizes a lifetime "expected credit loss" measurement objective for the recognition of credit losses for loans, held to maturity securities and other receivables at the time the financial asset is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. The methodology replaces the multiple existing impairment methods in Accounting principles generally accepted in the United States ("U.S. GAAP"), which generally require that a loss be incurred before it is recognized. For financial assets measured at amortized cost (e.g., cash and receivables from clients), the Company has concluded that there are de minimus expected credit losses based on the nature and contractual life or expected life of the financial assets and immaterial historic and expected losses. On January 1, 2020, the Company adopted Topic 326 using the modified retrospective approach for all in scope assets, which did not result in an adjustment to the opening balance in retained earnings. Revenue Recognition The Company may enter into licensing and collaboration agreements for product development, licensing, supply and manufacturing for its product pipeline. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations. These contracts are analyzed to identify all performance obligations forming part of these contracts. The transaction price of the contract is then determined. The transaction price is allocated between all performance obligations on a residual standalone selling price basis. The stand-alone selling price is estimated based on the comparable market prices, expected cost plus margin and the Company's historical experience. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. The following is a description of principal activities - separated by nature - from which the Company generates its revenue. Research and Development Revenue Revenues with corporate collaborators are recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement. Licensing and Collaboration Arrangements Licenses are considered to be right-to-use licenses. As such, the Company recognizes the licenses revenues at a point in time, upon granting the licenses. Milestone payments are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, research and other revenues in the period during which the adjustment is recognized. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is significant risk that the Company may not earn all of the milestone payments for each of its contracts. Royalties are typically calculated as a percentage of net sales realized by the Company's licensees of its products (including their sub-licensees), as specifically defined in each agreement. The licensees' sales generally consist of revenues from product sales of the Company's product pipeline and net sales are determined by deducting the Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, and the investment tax credits receivable. Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions. Financial instruments - Credit losses The Company accounts for estimated credit losses on financial assets measured at an amortized cost basis and certain off-balance sheet credit exposures in accordance with FASB Accounting Standards Codification ("ASC") 326 20, Financial Instruments - Credit Losses. FASB ASC 326 20 requires the Company to estimate expected credit losses over the life of its financial assets and certain off-balance sheet exposures as of the reporting date based on relevant information about past events, current conditions, and reasonable and supportable forecasts. The Company records the estimate of expected credit losses as an allowance for credit losses. For financial assets measured at an amortized cost basis the allowance for credit losses is reported as a valuation account on the balance sheet that is deducted from the asset's amortized cost basis. Changes in the allowance for credit losses are reported in Credit Loss expense. Accounts receivable The Company's accounts receivable relate to licensing and collaboration agreements for product development, licensing, supply and manufacturing agreements. These accounts receivable are short term in nature. The Company estimates expected credit losses over the life of the financial assets as of the reporting date based on relevant information about past events, current conditions, and reasonable and supportable forecasts. Investment Tax Credits Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed. Investment tax credits received in the year ended December 31, 2020 totaled $ Nil Inventory The Company values inventory at the lower of cost and net realizable value where net realizable value represents the expected sale price upon disposition less make-ready costs and the costs of disposal and transportation and determines the cost of raw material inventory using the average-cost method. The Company analyzes its inventory levels quarterly and adjusts inventory to its net realizable value, if required, for obsolete, or has a cost basis in excess of its expected net realizable value. Leasehold Improvements and Equipment Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: On the declining balance method - Laboratory and office equipment 20% Computer equipment 30% On the straight-line method - Leasehold improvements over the lease term Manufacturing equipment 5 - 10 years Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred. Leases Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. Substantially all of the Company's operating leases are comprised of office space and property leases. The finance leases are comprised of laboratory equipment leases. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's secured incremental borrowing rate for the same term as the underlying lease. In April 2020, the FASB issued a Staff Question-and-Answer ("Q&A") to clarify whether lease concessions related to the effects of COVID-19 require the application of the lease modification guidance under the new lease standard, which the Company adopted on January 1, 2019. Under the new leasing standard, an entity would have to determine, on a lease by lease basis, if a lease concession was the result of a new arrangement reached with the tenant, which would be accounted for under the lease modification framework, or if the lease concession was under the enforceable rights and obligations that existed in the original lease, which would be accounted for outside the lease modification framework. The Q&A provides entities with the option to elect to account for lease concessions as though the enforceable rights and obligations existed in the original lease as long as the total cash flows from the modified lease are substantially similar to the cash flows in the original lease. The Company has elected to use this option and, to the extent that a rent concession is granted as a deferral of payments but total payments are substantially the same, the Company will account for the concession as if no change has been made to the original lease. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease modifications result in remeasurement of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. The Company has elected not to recognize right-of-use assets and lease liabilities for short-tern leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material. Security Deposits Security deposits represent a refundable deposit paid to the landlord in accordance with the lease agreement and deposits held as guarantees by the Company's lenders in accordance with the lending facilities. The deposits will be repaid to the Company at the end of the lease. Impairment of Long-lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Foreign Currency Translation The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows: Gains and losses arising from foreign currency translation are included in other comprehensive income. Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Unrecognized Tax Benefits The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 "Income Taxes". ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision. Share-Based Payments The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation-Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company uses the Black-Scholes option pricing model to determine the fair value of the options. The Company measures compensation expense for its non-employee stock-based compensation under ASC 718, "Compensation-Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements as expense over the service period, as if the Company had paid cash for the services. Loss Per Share Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share. Fair Value Measurements ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Level 2: Level 3: In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. Short-term investments are classified Level 1. Fair Value of Financial Instruments The fair value represents management's best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization. Recent Accounting Pronouncements ASU 2020-06-Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity The FASB issued ASU 2020-06,1 which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. These amendments are effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes The FASB issued ASU 2019-12 which removes specific exceptions to the general principles in Topic 740 in Generally Accepted Accounting Principles (GAAP). It eliminates the need for an organization to analyze whether the following apply in a given period: -Exception to the incremental approach for intraperiod tax allocation; -Exceptions to accounting for basis differences when there are ownership changes in foreign investments; and -Exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also improves financial statement preparers' application of income tax-related guidance and simplifies GAAP for: -Franchise taxes that are partially based on income; -Transactions with a government that result in a step up in the tax basis of goodwill; -Separate financial statements of legal entities that are not subject to tax; and -Enacted changes in tax laws in interim periods. These amendments are effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

Short-term investments

Short-term investments	12 Months Ended
	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Short-term investments [Text Block]	5. Short-term investments As at December 31, 2020, short-term investments consisted of investments in mutual funds of $1 million (CAD$1.3 million) (2019 - $580 thousand (CAD$754 thousand)) and are with a Canadian financial institution having a high credit rating.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventory	6. Inventory Inventory as at December 31, 2020 consisted of raw materials in the amount of $244 thousand (2019 - $382 thousand). An amount of $138 was recognized in Research and development expenses.

Leasehold Improvements and Equi

Leasehold Improvements and Equipment	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Leasehold Improvements and Equipment [Text Block]	7. Leasehold improvements and Equipment 2020 2019 Accumulated Net Carrying Net Carrying Cost Depreciation Amount Amount Manufacturing equipment $ 4,819 $ 1,195 $ 3,624 $ 3,778 Laboratory and office equipment 1,409 993 416 498 Computer equipment 133 100 33 40 Leasehold improvements 3,424 1,646 1,778 2,049 $ 9,785 $ 3,934 $ 5,851 $ 6,365 From the balance of manufacturing equipment, an amount of $1,824 thousand (2019 - $1,788 thousand) represents assets which are still under construction as at December 31, 2020 and are consequently not depreciated. The commitment of the Company for the remainder of the project is as disclosed in note 12.

Bank indebtedness

Bank indebtedness	12 Months Ended
	Dec. 31, 2020
Bank Indebtedness [Abstract]
Bank indebtedness [Text Block]	8. Bank Indebtedness The Company's credit facility is subject to review annually and consists of an operating demand line of credit of up to CAD$250 thousand ($196 thousand) CAD$75 thousand ($59 thousand), CAD$425 thousand ($334 thousand). Borrowings under the operating demand line of credit bear interest at the Bank's prime lending rate plus 2%. The credit facility and term loan (see note 9) are secured by a first ranking movable hypothec on all present and future movable property of the Company for an amount of CAD$4,250,000 ($3,338,000) plus 20%, and a 50% guarantee by Export Development Canada, a Canadian Crown corporation export credit agency. The terms of the banking agreement require the Company to comply with certain debt service coverage and debt to net worth financial covenants on an annual basis at the end of the Company's fiscal year. As at December 31, 2020, the Company was not in compliance with its financial covenants and has not drawn on its credit facility. The Company has obtained a waiver from the lender.

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2020
Other Liabilities Disclosure [Abstract]
Long-Term Debt [Text Block]	9. Long-Term Debt The components of the Company’s debt are as follows: December 31, 2020 $ December 31, 2019 $ Term loan facility 732 1,005 Secured loan — 192 Total debt 732 1,197 Less: current portion 561 727 Total long-term debt 171 470 The Company’s term loan facility consists of a total of CAD$4 million ($3.14 million) bearing interest at the Bank’s prime lending rate plus 2.50%, with monthly principal repayments of CAD$62 thousand ($49 thousand). In April 2020, as a result of the global pandemic, the lender granted the Company an automatic six-month moratorium of capital repayments. The term loan is subject to the same security and financial covenants as the bank indebtedness (see note 8). Principal repayments due in each of the next two years are as follows: 2020 561 (CAD 714) 2021 171 (CAD 218) The secured loan was repaid in full during the year.

Convertible Debentures

Convertible Debentures	12 Months Ended
	Dec. 31, 2020
Convertible Debt [Abstract]
Convertible Debentures [Text Block]	10. Convertible Debentures On July 12, 2017, the Company closed its previously announced prospectus offering (the "Offering") of convertible unsecured subordinated debentures of the Corporation (the "Debentures") for gross aggregate proceeds of CAD$6,838,000 ($5,371,000). Pursuant to the Offering, the Corporation issued an aggregate principal amount of CAD$6,838,000 ($5,371,000) of Debentures at a price of CAD$1,000 ($785) per Debenture. The Debentures had a maturity date June 30, 2020 and interest at an annual rate of 8% payable semi-annually on the last day of June and December of each year, commencing on December 31, 2017. The interest may be paid in common shares at the option of the Corporation. The Debentures will be convertible at the option of the holders at any time prior to the close of business on the earlier of June 30, 2020 and the business day immediately preceding the date specified by the Corporation for redemption of Debentures. The conversion price will be CAD$1.35 ($1.06) (the "Conversion Price") per common share of the Corporation ("Share"), being a conversion rate of approximately 740 Shares per CAD$1,000 ($785) principal amount of Debentures, subject to adjustment in certain events. On August 8, 2017, the Company closed a second tranche of its prospectus Offering of convertible unsecured subordinated debentures of the Corporation for which a first closing took place on July 12, pursuant to which it had raised additional gross proceeds of CAD$762,000 ($598,000). Together with the principal amount of CAD$6,838,000 ($5,371,000) of Debentures issued on July 12, 2017, the Company issued a total aggregate principal amount of CAD$7,600,000 ($5,969,000) of Debentures at a price of CAD$1,000 ($785) per Debenture. On June 25, 2020, the debentureholders approved the extension of the maturity date of the convertible debentures from June 30, 2020 to June 30, 2022 and the conversion price was reduced from CAD$1.35 ($1.06) to CAD$0.50 ($0.39). This extension was accounted for as an extinguishment and the debenture were re-measured at fair value on June 30, 2020. This re-measurement resulted in a gain on extinguishment in the amount of CAD$547,000 ($401,000) recognized in finance and interest income. The components of the convertible debentures subsequent to the extension are as follows: December 31, 2020 Face value of the convertible debentures $ 5,848 Gain on extinguishment (430 ) Transaction costs (74 ) Accretion 117 Convertible debentures $ 5,461 The convertible debentures have been recorded as a liability. The accretion expense for the year ended December 31, 2020 amounts to CAD$398,000 ($297,000), compared to CAD$443,000 ($334,000) for the comparative period in 2019. During the year ended December 31, 2020, CAD$141,000 ($111,000) of convertible debentures were converted into 282,000 common shares at the option of the holders, resulting in an increase in additional paid-in capital of $103 thousand. Interest accrued during the year ended December 31, 2020 on the convertible debentures amounts to CAD$606 thousand ($452 thousand) out of which CAD$309 thousand ($218 thousand) was paid in cash on June 25, 2020 and CAD$297 thousand ($234 thousand) was paid by issuance of 887,880 common shares on December 31, 2020. Interest accrued during the year ended December 31, 2019 on the convertible debentures amounts to CAD$606 thousand ($457 thousand) out of which CAD$303 thousand ($229 thousand) was paid in cash on June 27, 2019 and CAD$303 thousand ($228 thousand) was paid by issuance of 415,179 common shares on December 31, 2019.

Convertible Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2020
Convertible Notes [Abstract]
Convertible Notes [Text Block]	11. Convertible Notes On May 8, 2018, the Company closed its previously announced offering by way of private placement (the “Offering”). In connection with the Offering, the Company issued 320 units (the “Units”) at a subscription price of $10,000 per Unit for gross proceeds of $3,200,000. A related party of the Company participated in the Offering and subscribed for an aggregate of two Units. Each Unit is comprised of (i) 7,940 common shares of the Corporation (“Common Shares”), (ii) a $5,000 convertible 6% note (a “Note”), and (iii) 7,690 warrants to purchase common shares of the Corporation (“Warrants”). Each Note bears interest at a rate of 6% (payable quarterly, in arrears, with the first payment being due on September 1, 2018), matures on June 1, 2021 and is convertible into Common Shares at a conversion price of $0.80 per Common Share. Each Warrant entitles its holder to purchase one Common Share at a price of $0.80 per Common Share until June 1, 2021. In connection with the Offering, the Company paid to the Agents a cash commission of approximately $157,800 in the aggregate and issued non-transferable agents’ warrants to the Agents, entitling the Agents to purchase 243,275 common shares at a price of $0.80 per share until June 1, 2021. Management has determined the value of the agents’ warrants to be $50,000. The proceeds of the Units are attributed to liability and equity components based on the fair value of each component as follows: Gross proceeds Transaction costs Net proceeds Common stock $ 1,627 $ 167 $ 1,460 Convertible notes 1,086 111 975 Warrants 487 50 437 $ 3,200 $ 328 $ 2,872 The convertible notes have been recorded as a liability. Total transactions costs in the amount of $111 The components of the convertible notes are as follows: December 31, 2020 December 31, 2019 Attributed value of net proceeds to convertible notes $ 975 $ 975 Accretion 511 280 Convertible note $ 1,486 $ 1,255 The interest on the convertible notes for the year ended December 31, 2020 amounts to $96,000 (2019: $96,000) and is recorded in financing and interest expense. The proceeds of the Units are attributed to liability and equity components based on the fair value of each component. Management has determined the value attributed to the common stock is $1,460 and $437 for the warrants issued, resulting in an increase in additional paid-in-capital of $1,897. On October 15, 2020, the Company announced the closing of an offering by way of private placement to certain investors in the United States of $1.2 million principal amount of 8% convertible notes due October 15, 2024. The Notes will bear interest at a rate of 8% per annum, payable quarterly, and will be convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.18 per Share. The Company intends to use the proceeds of the Offering for working capital purposes. In connection with the Offering, the Company paid to an agent a cash commission of approximately $85,000 in the aggregate and issued non-transferable warrants to the agent, entitling the holder to purchase 482,000 common shares at a price of $0.18 per Share until October 15, 2022. On October 23, 2020, the Company announced the closing of a second tranche of the Notes to certain investors in the United States of $557 thousand principal amount of 8% convertible notes due Oct 15, 2024. The Notes will bear interest at a rate of 8% per annum, payable quarterly, and will be convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.18 per Share. In connection with the Offering, the Company paid to an agent a cash commission of approximately $39,000 in the aggregate and issued non-transferable warrants to the agent, entitling the holder to purchase 222,800 common shares at a price of $0.18 per Share until October 15, 2022. Management has determined the value of the agents' warrants to be $44,000. The convertible notes have been recorded as a liability. Total transactions costs in the amount of $268 thousand were recorded against the liability. The accretion expense for the year ended December 31, 2020 amounts to $11. The warrants have been recorded as equity. The components of the convertible notes are as follows: December 31, 2020 Attributed value of net proceeds to convertible notes $ 1,494 Accretion 11 Convertible note $ 1,505 The interest on the convertible notes for the year ended December 31, 2020 amounts to $29,000 (2019: $ Nil

Commitments

Commitments	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments [Text Block]	12. Commitments The Company has initiated a project to expand the existing manufacturing facility. The Company has signed agreements in the amount of Euro 1,911 thousand with three suppliers with respect to equipment for solvent film manufacturing. As at December 31, 2020 an amount of Euro 1,425 thousand has been paid with respect to these agreements (note 8).

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Capital Stock [Text Block]	13. Capital Stock 2020 2019 Authorized - 200,000,000 common shares of $0.00001 par value 20,000,000 preferred shares of $0.00001 par value Issued - 111,429,532 (December 31, 2019: 93,942,652) common shares $ 1 $ 1 Public Offering On February 11, 2020, IntelGenx announced the closing of 16,317,000 units (the "Units") at a price of CAD$0.50 ($0.37) for gross proceeds of CAD$8,158,500 ($6,137,000). Each Unit consists of one share of common stock of the Company and one warrant entitling the holder to purchase one share of common stock of the Company at an exercise price of CAD$0.75 ($0.56) per share. The Warrants are exercisable immediately and will expire on the third anniversary of the date of their issuance. Management has determined the value attributed to common stock is $3,912 thousand and $1,207 thousand for the warrants issued, resulting in an increase in additional paid-in-capital of $5,119 thousand. In connection with the Offering, the Company paid to the Agents a cash commission of approximately CAD$763,000 ($572,000) in the aggregate and issued non-transferable agents' warrants to the Agents, entitling the Agents to purchase 1,142,190 common shares at a price of CAD$0.75 ($0.56) per share until February 11, 2023. Management has determined the value of the agents' warrants to be $125,000, resulting in an increase in additional paid-in-capital of $125,000. The proceeds of the Units are attributed to equity components based on the fair value of each component as follows: Gross proceeds Transaction costs Net proceeds Common stock $ 4,690 $ 778 $ 3,912 Warrants 1,447 240 1,207 $ 6,137 $ 1,018 $ 5,119 Stock options During the year ended December 31, 2020 there were no stock options exercised. During the year ended December 31, 2019 a total of 50,000 stock options were exercised for 50,000 common shares having a par value of $0 thousand in aggregate, for cash consideration of $21 thousand, resulting in an increase in additional paid-in capital of $21 thousand. Stock-based compensation of $193 thousand and $333 thousand was recorded during the year ended December 31, 2020 and 2019 respectively. An amount of $156 thousand (2019 - $286 thousand) expensed relates to stock options granted to employees and an amount of $37 thousand (2019- $47 thousand) relates to stock options granted to consultants during the year ended December 31, 2019. As at December 31, 2020 the Company has $180 thousand (2019 - $157 thousand) of unrecognized stock-based compensation, of which $ Nil

Additional Paid-In Capital

Additional Paid-In Capital	12 Months Ended
	Dec. 31, 2020
Additional Paid in Capital [Abstract]
Additional Paid-In Capital [Text Block]	14. Additional Paid-In Capital Stock Options On May 9, 2016, the Board of Directors of the Company adopted the 2016 Stock Option Plan which amended and restated the 2006 Stock Option. As a result of the adoption of the 2016 Stock Option Plan, no additional options will be granted under the 2006 Stock Option Plan and all previously granted options will be governed by the 2016 Stock Option Plan. The 2016 Stock Option Plan permits the granting of options to officers, employees, directors and eligible consultants of the Company. A total of 9,347,747 shares of common stock were reserved for issuance under this plan, which includes stock options granted under the previous 2006 Stock Option Plan. Options may be granted under the 2016 Stock Option Plan on terms and at prices as determined by the Board except that the options cannot be granted at less than the market closing price of the common stock on the TSX-V. on the date prior to the grant. Each option will be exercisable after the period or periods specified in the option agreement, but no option may be exercised after the expiration of 10 years from the date of grant. The 2016 Stock Option Plan provides the Board with more flexibility when setting the vesting schedule for options which was otherwise fixed in the 2006 Stock Option Plan. The fair value of options granted has been estimated according to the Black-Scholes valuation model and based on the weighted average of the following assumptions for options granted to employees and directors during the years ended: 2020 2019 Exercise price 0.27 0.69 Expected volatility 77% 64% Expected life 5.63 years 5.63 years Risk-free interest rate 0.39% 2.18% Dividend yield Nil Nil The weighted average fair value of the options granted to employees during the year ended December 31, 2020 is $0.13 (2019 - $0.40). Information with respect to employees and directors stock option activity for 2019 and 2020 is as follows: Number of options Weighted average exercise price $ Outstanding - January 1, 2019 3,854,818 0.68 Granted 100,000 0.69 Forfeited (37,500 ) (0.66 ) Expired (402,500 ) (0.67 ) Exercised (50,000 ) (0.41 ) Outstanding - December 31, 2019 3,464,818 0.68 Granted 1,390,000 0.27 Expired (225,000 ) (0.61 ) Outstanding - December 31, 2020 4,629,818 0.56 Information with respect to consultant's stock option activity for 2019 and 2020 is as follows: Number of options Weighted average exercise price $ Outstanding - January 1, 2019 and 2020 550,000 0.72 Outstanding - December 31, 2019 and 2020 550,000 0.72 Details of stock options outstanding as at December 31, 2020 are as follows: Outstanding options Exercisable options Exercise prices $ Number of options Weighted average remaining contractual life (years) Weighted average exercise price $ Aggregate intrinsic value $ Number of options Weighted average exercise price $ Aggregate intrinsic value $ 0.27 1,390,000 2.66 0.07 — 0.00 0.41 275,000 0.01 0.02 275,000 0.03 0.58 600,000 0.52 0.07 600,000 0.09 0.66 200,000 0.28 0.03 200,000 0.04 0.69 100,000 0.16 0.01 75,000 0.01 0.70 475,000 0.18 0.06 475,000 0.09 0.73 525,000 0.53 0.07 525,000 0.10 0.76 905,000 1.27 0.13 905,000 0.18 0.77 359,818 0.46 0.05 359,818 0.07 0.78 100,000 0.01 0.02 100,000 0.02 0.89 250,000 0.29 0.04 250,000 0.06 5,179,818 6.37 0.57 — 3,764,818 0.69 — Stock-based compensation expense recognized in 2020 with regards to the stock options was $193 thousand (2019: $333 thousand). As at December 31, 2020 the Company has $180 thousand (2019 - $157 thousand) of unrecognized stock-based compensation, of which $ Nil Warrants Information with respect to warrant activity for 2019 and 2020 is as follows: Number of warrants (All Exercisable) Weighted average exercise price $ Outstanding - January 1, 2019 and 2020 12,904,397 0.9470 Granted 18,163,990 0.5453 Outstanding - December 31, 2020 31,068,387 0.7125 Deferred Share Units ("DSUs") Effective February 7, 2018, the Board approved a Deferred Share Unit Plan (DSU Plan) to compensate non-employee directors as part of their annual remuneration. Under the DSU Plan, the Board may grant Deferred Share Units ("DSUs") to the participating directors at its discretion and, in addition, each participating director may elect to receive all or a portion of his or her annual cash stipend in the form of DSUs. To the extent DSUs are granted, the amount of compensation that is deferred is converted into a number of DSUs, as determined by the market price of our Common Stock on the effective date of the election. These DSUs are converted back into a cash amount at the expiration of the deferral period based on the market price of our Common Stock on the expiration date and paid to the director in cash in accordance with the payout terms of the DSU Plan. As the DSUs are on a cash-only basis, no shares of Common Stock will be reserved or issued in connection with the DSUs. On March 27, 2019, 271,740 DSUs have been granted under the DSU Plan, accordingly, an amount of $128 thousand has been recognized in general and administrative expenses. No DSUs were granted in 2020. Performance and Restricted Share Units ("PRSUs") At the Annual Meeting on May 8, 2018, the shareholders approved the IntelGenx Technologies Corp. Performance and Restricted Share Unit Plan (PRSU Plan) which the Board of Directors had approved on March 19, 2018. The primary purpose of this PRSU Plan is to provide the Company with a share-related mechanism to attract, retain and motivate qualified executive officers of the Company and its Subsidiaries and to reward such executive officers for their contributions toward the long-term goals and success of the Company and to enable and encourage such executive officers to acquire shares of Common Stock as long-term investments and proprietary interests in the Company. As at December 31, 2020, 53,846 rewards have been issued under the PRSU Plan, accord. No rewards were granted under the PRSU Plan in 2019 and 2020.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	15. Income Taxes Income taxes reported differ from the amount computed by applying the statutory rates to net income (losses). The reasons are as follows: 2020 2019 Statutory income taxes $ (1,716 ) $ (2,398 ) Net operating losses for which no tax benefits have been recorded 1,048 1,189 Deficiency of depreciation over capital cost allowance (28 ) (178 ) Non-deductible expenses 455 667 Undeducted research and development expenses 409 820 Investment tax credit (168 ) (100 ) $ — $ — The major components of the deferred tax assets classified by the source of temporary differences are as follows: 2020 2019 Leasehold improvements and equipment $ 445 $ 440 Net operating losses carryforward 8,684 6,396 Undeducted research and development expenses 3,534 2,903 Non-refundable tax credits carryforward 2,506 2,082 15,169 11,821 Valuation allowance (15,169 ) (11,821 ) $ — $ — As at December 31, 2020, management determined that enough uncertainty existed relative to the realization of deferred income tax asset balances to warrant the application of a full valuation allowance. Management continues to believe that enough uncertainty exists relative to the realization of the remaining deferred income tax asset balances such that no recognition of deferred income tax assets is warranted. There were Canadian and provincial net operating losses of approximately $31,673 thousand (2019: $23,101 thousand) and $33,905 thousand (2019: $25,265 thousand) respectively, that may be applied against earnings of future years. Utilization of the net operating losses is subject to significant limitations imposed by the change in control provisions. Canadian and provincial losses will be expiring between 2026 and 2040. A portion of the net operating losses may expire before they can be utilized. As at December 31, 2020, the Company had non-refundable tax credits of $2,802 thousand (2019: $2,486 thousand) of which $8 thousand is expiring in 2026, $10 thousand is expiring in 2027, $177 thousand is expiring in 2028, $155 thousand is expiring in 2029, $132 thousand is expiring in 2030, $141 thousand is expiring in 2031, $176 thousand is expiring in 2032, $117 thousand is expiring in 2033, $89 thousand expiring in 2034, $104 thousand is expiring in 2035, $144 thousand expiring in 2036, $275 thousand is expiring in 2037, $594 thousand expiring in 2038, $359 thousand expiring in 2039 and $298 thousand expiring in 2040 and undeducted research and development expenses of $15,302 thousand (2019: $14,282 thousand) with no expiration date. The deferred tax benefit of these items was not recognized in the accounts as it has been fully provided for. Unrecognized Tax Benefits The Company does not have any unrecognized tax benefits. Tax Years and Examination The Company files tax returns in each jurisdiction in which it is registered to do business. For each jurisdiction a statute of limitations period exists. After a statute of limitations period expires, the respective tax authorities may no longer assess additional income tax for the expired period. Similarly, the Company is no longer eligible to file claims for refund for any tax that it may have overpaid. The following table summarizes the Company's major tax jurisdictions and the tax years that remain subject to examination by these jurisdictions as of December 31, 2020: Tax Jurisdictions Tax Years Federal - Canada 2016 and onward Provincial - Quebec 2016 and onward Federal USA 2016 onward

Revenues

Revenues	12 Months Ended
	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenues [Text Block]	16. Revenues The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues: December 31, 2020 December 31, 2019 Research and development agreements $ 562 $ 742 Licensing agreements 982 — $ 1,544 $ 742 The following table presents our revenues disaggregated by timing of recognition: December 31, 2020 December 31, 2019 Product and services transferred at point in time $ 1,185 $ 372 Products and services transferred over time 359 370 $ 1,544 $ 742 The following table presents our revenues disaggregated by geography, based on the billing addresses of our customers: December 31, 2020 December 31, 2019 Europe $ 795 534 Canada 708 208 United States 41 — $ 1,544 $ 742 Remaining performance obligations As at December 31, 2020, the aggregate amount of the transaction price allocated to the remaining performance obligation is $1,425 representing research and development agreements, the majority of which is expected to be recognized in the next twelve months. The Company is also eligible to receive up to $2,558 in research and development milestone payments, approximately 100% of which is expected to be recognized in the next three years; up to $433 in commercial sales milestone payments which are wholly dependent on the marketing efforts of our development partners. In addition, the Company is entitled to receive royalties on potential sales. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about the remaining performance obligations that have original expected durations of one year or less.

Statement of Cash Flows Informa

Statement of Cash Flows Information	12 Months Ended
	Dec. 31, 2020
Supplemental Cash Flow Information [Abstract]
Statement of Cash Flows Information [Text Block]	17. Statement of Cash Flows Information In US$ thousands 2020 2019 Additional Cash Flow Information: Interest paid $ 441 $ 465

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Leases [Text Block]	18. Leases Operating leases Substantially all our operating lease right-of-use assets and operating lease liability represents leases for office space and property to conduct our business. The operating lease expense for the year ended December 31, 2020 included in general and administrative expenses is $87 thousand. The cash outflows from operating leases for the year ended December 31, 2020 was $91 thousand. During the year ended December 31, 2020, the Company was granted a rent concession by the landlord due to the COVID-19 pandemic that resulted in a negative variable lease expense in the amount of $64 thousand. The weighted average remaining lease term and the weighted average discount rate for operating leases at December 31, 2020 were 5.2 years and 10%, respectively. The following table reconciles the undiscounted cash flows for the operating leases as et December 31, 2020 to the operating lease liabilities recorded on the balance sheet; Operating Leases 2021 $ 155 2022 159 2023 161 2024 164 2025 164 Thereafter 28 Total undiscounted lease payments 831 Less: Interest 208 Present value of lease liabilities $ 623 Current portion of operating lease liability $ 141 Operating lease liability $ 482 Finance leases Substantially all our finance lease right-of-use assets and finance lease liability represents leases for laboratory equipment to conduct our business. The cash outflows from finance leases for the year ended December 31, 2020 was $2 thousand. The weighted average remaining lease term and the weighted average discount rate for finance leases at December 31, 2020 were 4 years and 6.43%, respectively. The following table reconciles the undiscounted cash flows for the finance leases as at December 31, 2020 to the finance lease liabilities recorded on the balance sheet: Finance Leases 2021 $ 32 2022 32 2023 32 2024 29 Total undiscounted lease payments 125 Less: Interest 16 Present value of lease liabilities $ 109 Current portion of finance lease liability $ 25 Finance lease liability $ 84

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions [Text Block]	19. Related Party Transactions Included in management salaries are $20 thousand (2019 - $67 thousand) for options granted to the Chief Executive Officer, $51 thousand (2019 - $50 thousand) for options granted to the President and Chief Financial Officer, $10 thousand (2019 - $29) for options granted to the Vice-President, Research and Development, $10 thousand (2019 - $29) for options granted to the Vice-President, Business and Corporate Development, and $30 thousand (2019 - $36) for options granted to the Vice-President, Operations under the 2016 Stock Option Plans. Included in general and administrative expenses are director fees of $233 thousand (2019: $231 thousand). The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed upon by the related parties.

Basic and Diluted Loss Per Comm

Basic and Diluted Loss Per Common Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Basic and Diluted Loss Per Common Share [Text Block]	20. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the year. Common equivalent shares from stock options, warrants and convertible debentures are also included in the diluted per share calculations unless the effect of the inclusion would be antidilutive.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Event [Text Block]	21. Subsequent Events On January 11, 2021, 150,000 options to purchase common stock were granted to an employee under the 2016 Stock Option Plan. The options have an exercise price of $0.27. The options granted vest over a period of 2 years at a rate of 25% every six months and expire 10 years after the grant date. Subsequent to the end of the year, CAD$301,000 ($236,000) of convertible debentures were converted into 602,000 common shares at the option of the holders. On March 15, 2021, the Company announced a strategic partnership with Atai Life Sciences and a proposed TSX graduation. The announcement stated that the Company had agreed to the terms of a strategic partnership with Atai Life Sciences (" atai Strategic Development Agreement Under a strategic development agreement, atai and IntelGenx will cooperate to conduct research and development projects in areas relating to the parties' respective technologies. A portion of the funds (20%) that we will receive through atai's equity investment under the securities purchase agreement described below will be available to be credited against the costs of the Company the research and development projects. So long as atai maintains certain levels of its initial equity ownership in us, atai will have exclusive commercialization rights in the field of compounds for the prevention or treatment of mental health diseases or disorders or compounds that have psychedelic, entactogenic and/or oneirophrenic properties, but excluding certain specific compounds and veterinary applications. The commercialization of any technologies that result from the research and development projects under the strategic development agreement will be subject to agreements to be negotiated, as well as to specified pricing and royalty terms for manufacturing conducted by us or third parties. Securities Purchase Agreement Under a securities purchase agreement, atai has agreed to purchase 37,300,000 shares of common stock of the Company and 22,380,000 warrants for aggregate gross proceeds of $12,346,300 following receipt of shareholders' approval at the meeting. Each warrant will entitle atai to purchase one share at a price of $0.35 for a period of three years from closing of the initial investment. The securities purchase agreement also provides atai with the right to subscribe (in cash, or in certain circumstances, atai equity) for up to 130,000,000 additional units for a period of three years from the closing of the initial investment. Each additional unit will be comprised of (i) one share of common stock and (ii) one half of one warrant. The price for the additional units will be (i) until the date which is 12 months following the closing, $0.331 (subject to certain exceptions), and (ii) following the date which is 12 months following the closing, the lower of (A) a 20% premium to the market price on the date of purchase, and (B) $0.50 if purchased in the second year following closing and $0.75 if purchased in third year following closing. Each additional warrant will entitle atai, for a period of three years from the date of issuance, to purchase one share at the lesser of either (i) a 20% premium to the price of the corresponding additional share, or (ii) the price per share under which shares of the Company are issued under convertible instruments that were outstanding on February 16, 2021, the date on which the parties entered into a non-binding letter of intent to enter into a definitive securities purchase agreement, provided that atai may not exercise additional warrants to purchase more than the lesser of (x) 44,000,000 common shares of the Company, and (y) the number of common shares issued by the Company under outstanding convertibles. Under the securities purchase agreement, the Company also granted atai a pro-rata equity participation right for any issuances of new securities, subject to certain exceptions. Following the initial closing, atai will hold approximately 25% (approximately 35% on a partially diluted basis) of the issued and outstanding shares and therefore become a new "Control Person" of the Company as such term is defined under the policies of the Exchange. Based on the number of issued and outstanding shares and outstanding convertible instruments on the date hereof, assuming the full exercise of its option to acquire the additional units and exercise of the initial warrants and additional warrants, atai would hold approximately 60% (approximately 60% on a partially diluted basis) of the issued and outstanding Shares. Proposed Graduation to the Toronto Stock Exchange Under the Securities Purchase Agreement, we have agreed to use reasonable efforts to list our shares on the TSX with a target to achieve such listing shortly after the initial closing contemplated by the securities purchase agreement and we intend to promptly submit a listing application to the TSX. There is no assurance that the TSX will approve the listing application and any listing of the shares of Common Stock on the TSX is subject to us meeting all of the listing requirements of and obtaining the approval of the TSX. The Additional Units Warrant is only exercisable if our shares of Common Stock are listed on the TSX. Purchaser Rights Agreement Under the purchaser rights agreement, atai will have the right to appoint nominees in the same proportion to the number of board members of the Company as the shares then held by atai, registration rights, and financial and other information rights. The Company will have the right to terminate the purchaser rights agreement if atai ceases to own a certain amount of the Company's equity. Term Loan atai has granted to the Company a secured loan in the amount of $2,000,000, bearing interest at 8%. The loan is repayable on the date that is 120 days following the date of the Meeting, but in any event not later than September 30, 2021. The securities purchase agreement provides that an amendment is to be entered into at the initial closing of the atai investment under which the maturity date will be following the first closing of a subscription for additional units if the proceeds from such subscription amount to at least $3,000,000. The loan provides for the possibility of an additional advance to the Company of up to $500,000, subject to certain conditions. The loan is guaranteed by the Company and secured by all of present and future fixed assets of the Company, excluding any intellectual property or technology controlled or owned by the Company. The Company has applied approximately CA$800,000 ($628,000) from the loan to fully repay the outstanding amount on the Company's credit facilities with its Bank. The Company intends to use the balance of the loan for general working capital purposes.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Revenue [Policy Text Block]	Revenue Recognition The Company may enter into licensing and collaboration agreements for product development, licensing, supply and manufacturing for its product pipeline. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations. These contracts are analyzed to identify all performance obligations forming part of these contracts. The transaction price of the contract is then determined. The transaction price is allocated between all performance obligations on a residual standalone selling price basis. The stand-alone selling price is estimated based on the comparable market prices, expected cost plus margin and the Company's historical experience. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. The following is a description of principal activities - separated by nature - from which the Company generates its revenue. Research and Development Revenue Revenues with corporate collaborators are recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement. Licensing and Collaboration Arrangements Licenses are considered to be right-to-use licenses. As such, the Company recognizes the licenses revenues at a point in time, upon granting the licenses. Milestone payments are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, research and other revenues in the period during which the adjustment is recognized. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is significant risk that the Company may not earn all of the milestone payments for each of its contracts. Royalties are typically calculated as a percentage of net sales realized by the Company's licensees of its products (including their sub-licensees), as specifically defined in each agreement. The licensees' sales generally consist of revenues from product sales of the Company's product pipeline and net sales are determined by deducting the
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, and the investment tax credits receivable. Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.
Financial instruments - Credit losses [Policy Text Block]	Financial instruments - Credit losses The Company accounts for estimated credit losses on financial assets measured at an amortized cost basis and certain off-balance sheet credit exposures in accordance with FASB Accounting Standards Codification ("ASC") 326 20, Financial Instruments - Credit Losses. FASB ASC 326 20 requires the Company to estimate expected credit losses over the life of its financial assets and certain off-balance sheet exposures as of the reporting date based on relevant information about past events, current conditions, and reasonable and supportable forecasts. The Company records the estimate of expected credit losses as an allowance for credit losses. For financial assets measured at an amortized cost basis the allowance for credit losses is reported as a valuation account on the balance sheet that is deducted from the asset's amortized cost basis. Changes in the allowance for credit losses are reported in Credit Loss expense.
Accounts receivable [Policy Text Block]	Accounts receivable The Company's accounts receivable relate to licensing and collaboration agreements for product development, licensing, supply and manufacturing agreements. These accounts receivable are short term in nature. The Company estimates expected credit losses over the life of the financial assets as of the reporting date based on relevant information about past events, current conditions, and reasonable and supportable forecasts.
Investment Tax Credits [Policy Text Block]	Investment Tax Credits Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed. Investment tax credits received in the year ended December 31, 2020 totaled $ Nil
Inventory [Policy Text Block]	Inventory The Company values inventory at the lower of cost and net realizable value where net realizable value represents the expected sale price upon disposition less make-ready costs and the costs of disposal and transportation and determines the cost of raw material inventory using the average-cost method. The Company analyzes its inventory levels quarterly and adjusts inventory to its net realizable value, if required, for obsolete, or has a cost basis in excess of its expected net realizable value.
Leasehold Improvements and Equipment [Policy Text Block]	Leasehold Improvements and Equipment Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: On the declining balance method - Laboratory and office equipment 20% Computer equipment 30% On the straight-line method - Leasehold improvements over the lease term Manufacturing equipment 5 - 10 years Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.
Leases [Policy Text Block]	Leases Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. Substantially all of the Company's operating leases are comprised of office space and property leases. The finance leases are comprised of laboratory equipment leases. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's secured incremental borrowing rate for the same term as the underlying lease. In April 2020, the FASB issued a Staff Question-and-Answer ("Q&A") to clarify whether lease concessions related to the effects of COVID-19 require the application of the lease modification guidance under the new lease standard, which the Company adopted on January 1, 2019. Under the new leasing standard, an entity would have to determine, on a lease by lease basis, if a lease concession was the result of a new arrangement reached with the tenant, which would be accounted for under the lease modification framework, or if the lease concession was under the enforceable rights and obligations that existed in the original lease, which would be accounted for outside the lease modification framework. The Q&A provides entities with the option to elect to account for lease concessions as though the enforceable rights and obligations existed in the original lease as long as the total cash flows from the modified lease are substantially similar to the cash flows in the original lease. The Company has elected to use this option and, to the extent that a rent concession is granted as a deferral of payments but total payments are substantially the same, the Company will account for the concession as if no change has been made to the original lease. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease modifications result in remeasurement of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. The Company has elected not to recognize right-of-use assets and lease liabilities for short-tern leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material.
Security Deposits [Policy Text Block]	Security Deposits Security deposits represent a refundable deposit paid to the landlord in accordance with the lease agreement and deposits held as guarantees by the Company's lenders in accordance with the lending facilities. The deposits will be repaid to the Company at the end of the lease.
Impairment of Long-lived Assets [Policy Text Block]	Impairment of Long-lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable.
Foreign Currency Translation [Policy Text Block]	Foreign Currency Translation The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows: Gains and losses arising from foreign currency translation are included in other comprehensive income.
Income Taxes [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Unrecognized Tax Benefits [Policy Text Block]	Unrecognized Tax Benefits The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 "Income Taxes". ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision.
Share-Based Payment [Policy Text Block]	Share-Based Payments The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation-Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company uses the Black-Scholes option pricing model to determine the fair value of the options. The Company measures compensation expense for its non-employee stock-based compensation under ASC 718, "Compensation-Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements as expense over the service period, as if the Company had paid cash for the services.
Loss Per Share [Policy Text Block]	Loss Per Share Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share.
Fair Value Measurements [Policy Text Block]	Fair Value Measurements ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Level 2: Level 3: In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. Short-term investments are classified Level 1.
Fair Value of Financial Instruments [Policy Text Block]	Fair Value of Financial Instruments The fair value represents management's best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization.
Recent Accounting Pronouncements [Policy Text Block]	Recent Accounting Pronouncements ASU 2020-06-Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity The FASB issued ASU 2020-06,1 which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. These amendments are effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes The FASB issued ASU 2019-12 which removes specific exceptions to the general principles in Topic 740 in Generally Accepted Accounting Principles (GAAP). It eliminates the need for an organization to analyze whether the following apply in a given period: -Exception to the incremental approach for intraperiod tax allocation; -Exceptions to accounting for basis differences when there are ownership changes in foreign investments; and -Exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also improves financial statement preparers' application of income tax-related guidance and simplifies GAAP for: -Franchise taxes that are partially based on income; -Transactions with a government that result in a step up in the tax basis of goodwill; -Separate financial statements of legal entities that are not subject to tax; and -Enacted changes in tax laws in interim periods. These amendments are effective for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements [Abstract]
Schedule of estimated useful lives of leasehold improvements and equipment [Table Text Block]	On the declining balance method - Laboratory and office equipment 20% Computer equipment 30% On the straight-line method - Leasehold improvements over the lease term Manufacturing equipment 5 - 10 years

Leasehold Improvements and Eq_2

Leasehold Improvements and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements [Abstract]
Schedule of leasehold improvements and equipment [Table Text Block]	2020 2019 Accumulated Net Carrying Net Carrying Cost Depreciation Amount Amount Manufacturing equipment $ 4,819 $ 1,195 $ 3,624 $ 3,778 Laboratory and office equipment 1,409 993 416 498 Computer equipment 133 100 33 40 Leasehold improvements 3,424 1,646 1,778 2,049 $ 9,785 $ 3,934 $ 5,851 $ 6,365

Long-term debt (Tables)

Long-term debt (Tables)	12 Months Ended
	Dec. 31, 2020
Other Liabilities Disclosure [Abstract]
Schedule of term loan [Table Text Block]	December 31, 2020 $ December 31, 2019 $ Term loan facility 732 1,005 Secured loan — 192 Total debt 732 1,197 Less: current portion 561 727 Total long-term debt 171 470
Schedule of term loan principal repayments [Table Text Block]	2020 561 (CAD 714) 2021 171 (CAD 218)

Convertible Debentures (Tables)

Convertible Debentures (Tables)	12 Months Ended
	Dec. 31, 2020
Convertible Debt [Abstract]
Schedule of convertible debt [Table Text Block]	December 31, 2020 Face value of the convertible debentures $ 5,848 Gain on extinguishment (430 ) Transaction costs (74 ) Accretion 117 Convertible debentures $ 5,461

Convertible Notes (Tables)

Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Instrument [Line Items]
Schedule of Capital Units [Table Text Block]	Gross proceeds Transaction costs Net proceeds Common stock $ 1,627 $ 167 $ 1,460 Convertible notes 1,086 111 975 Warrants 487 50 437 $ 3,200 $ 328 $ 2,872
6% convertible notes [Member]
Debt Instrument [Line Items]
Schedule of Components of the Convertible Notes [Table Text Block]	December 31, 2020 December 31, 2019 Attributed value of net proceeds to convertible notes $ 975 $ 975 Accretion 511 280 Convertible note $ 1,486 $ 1,255
8% convertible notes [Member]
Debt Instrument [Line Items]
Schedule of Components of the Convertible Notes [Table Text Block]	December 31, 2020 Attributed value of net proceeds to convertible notes $ 1,494 Accretion 11 Convertible note $ 1,505

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Schedule of Stock by Class [Table Text Block]	2020 2019 Authorized - 200,000,000 common shares of $0.00001 par value 20,000,000 preferred shares of $0.00001 par value Issued - 111,429,532 (December 31, 2019: 93,942,652) common shares $ 1 $ 1
Schedule Of Proceeds Of Equity Components Based On Fair Value [Table Text Block]	Gross proceeds Transaction costs Net proceeds Common stock $ 4,690 $ 778 $ 3,912 Warrants 1,447 240 1,207 $ 6,137 $ 1,018 $ 5,119

Additional Paid-In Capital (Tab

Additional Paid-In Capital (Tables)	12 Months Ended
	Dec. 31, 2020
Additional Paid in Capital [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2020 2019 Exercise price 0.27 0.69 Expected volatility 77% 64% Expected life 5.63 years 5.63 years Risk-free interest rate 0.39% 2.18% Dividend yield Nil Nil
Schedule of Stock Option Activity to Employees and Directors [Table Text Block]	Number of options Weighted average exercise price $ Outstanding - January 1, 2019 3,854,818 0.68 Granted 100,000 0.69 Forfeited (37,500 ) (0.66 ) Expired (402,500 ) (0.67 ) Exercised (50,000 ) (0.41 ) Outstanding - December 31, 2019 3,464,818 0.68 Granted 1,390,000 0.27 Expired (225,000 ) (0.61 ) Outstanding - December 31, 2020 4,629,818 0.56
Schedule of Stock Option Activity to Consultants [Table Text Block]	Number of options Weighted average exercise price $ Outstanding - January 1, 2019 and 2020 550,000 0.72 Outstanding - December 31, 2019 and 2020 550,000 0.72
Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity [Table Text Block]	Outstanding options Exercisable options Exercise prices $ Number of options Weighted average remaining contractual life (years) Weighted average exercise price $ Aggregate intrinsic value $ Number of options Weighted average exercise price $ Aggregate intrinsic value $ 0.27 1,390,000 2.66 0.07 — 0.00 0.41 275,000 0.01 0.02 275,000 0.03 0.58 600,000 0.52 0.07 600,000 0.09 0.66 200,000 0.28 0.03 200,000 0.04 0.69 100,000 0.16 0.01 75,000 0.01 0.70 475,000 0.18 0.06 475,000 0.09 0.73 525,000 0.53 0.07 525,000 0.10 0.76 905,000 1.27 0.13 905,000 0.18 0.77 359,818 0.46 0.05 359,818 0.07 0.78 100,000 0.01 0.02 100,000 0.02 0.89 250,000 0.29 0.04 250,000 0.06 5,179,818 6.37 0.57 — 3,764,818 0.69 —
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]	Number of warrants (All Exercisable) Weighted average exercise price $ Outstanding - January 1, 2019 and 2020 12,904,397 0.9470 Granted 18,163,990 0.5453 Outstanding - December 31, 2020 31,068,387 0.7125

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2020 2019 Statutory income taxes $ (1,716 ) $ (2,398 ) Net operating losses for which no tax benefits have been recorded 1,048 1,189 Deficiency of depreciation over capital cost allowance (28 ) (178 ) Non-deductible expenses 455 667 Undeducted research and development expenses 409 820 Investment tax credit (168 ) (100 ) $ — $ —
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2020 2019 Leasehold improvements and equipment $ 445 $ 440 Net operating losses carryforward 8,684 6,396 Undeducted research and development expenses 3,534 2,903 Non-refundable tax credits carryforward 2,506 2,082 15,169 11,821 Valuation allowance (15,169 ) (11,821 ) $ — $ —
Schedule of Tax years and Jurisdictions [Table Text Block]	Tax Jurisdictions Tax Years Federal - Canada 2016 and onward Provincial - Quebec 2016 and onward Federal USA 2016 onward

Revenues (Tables)

Revenues (Tables)	12 Months Ended
	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue [Table Text Block]	December 31, 2020 December 31, 2019 Research and development agreements $ 562 $ 742 Licensing agreements 982 — $ 1,544 $ 742
Schedule of revenue, remaining performance obligation, expected timing of satisfaction [Table Text Block]	December 31, 2020 December 31, 2019 Product and services transferred at point in time $ 1,185 $ 372 Products and services transferred over time 359 370 $ 1,544 $ 742
Schedule of revenue from external customers and long-lived assets, by geographical areas [Table Text Block]	December 31, 2020 December 31, 2019 Europe $ 795 534 Canada 708 208 United States 41 — $ 1,544 $ 742

Statement of Cash Flows Infor_2

Statement of Cash Flows Information (Tables)	12 Months Ended
	Dec. 31, 2020
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	In US$ thousands 2020 2019 Additional Cash Flow Information: Interest paid $ 441 $ 465

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of reconciles undiscounted cash flows for operating leases [Table Text Block]	Operating Leases 2021 $ 155 2022 159 2023 161 2024 164 2025 164 Thereafter 28 Total undiscounted lease payments 831 Less: Interest 208 Present value of lease liabilities $ 623
Schedule of operating lease liabilities [Table Text Block]	Current portion of operating lease liability $ 141 Operating lease liability $ 482
Schedule of reconciles undiscounted cash flows for finance leases [Table Text Block]	Finance Leases 2021 $ 32 2022 32 2023 32 2024 29 Total undiscounted lease payments 125 Less: Interest 16 Present value of lease liabilities $ 109
Schedule of finance leases liabilities [Table Text Block]	Current portion of finance lease liability $ 25 Finance lease liability $ 84

Going Concern (Narrative) (Deta

Going Concern (Narrative) (Details) $ in Thousands	Dec. 31, 2020USD ($)
Going Concern [Abstract]
Cash and short-term investments	$ 2,243

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Investment Tax Credit		$ 416

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details)	12 Months Ended
	Dec. 31, 2020
Laboratory and office equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Depreciation Methods	declining balance method
Property Plant and Equipment, Estimated Useful Live Depreciation Methods Percentage	20.00%
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Depreciation Methods	declining balance method
Property Plant and Equipment, Estimated Useful Live Depreciation Methods Percentage	30.00%
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Depreciation Methods	straight-line method
Property Plant And Equipment, Estimated Useful Live Depreciation Methods Description	over the lease term
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Depreciation Methods	straight-line method
Manufacturing equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Manufacturing equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years

Short-term investments (Narrati

Short-term investments (Narrative) (Details) $ in Thousands, $ in Thousands	Dec. 31, 2020CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019CAD ($)	Dec. 31, 2019USD ($)
Cash and Cash Equivalents [Line Items]
Short-term investments		$ 1,038		$ 580
Mutual Fund [Member]
Cash and Cash Equivalents [Line Items]
Short-term investments	$ 1,300	$ 1,000	$ 754	$ 580

Inventory (Narrative) (Details)

Inventory (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials inventory	$ 244	$ 244	$ 382
Research and development expense	$ 138	$ 2,637	$ 3,774

Leasehold Improvements and Eq_3

Leasehold Improvements and Equipment (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment, Net	$ 5,851	$ 6,365
Asset not yet in service [Member]
Property, Plant and Equipment, Net	$ 1,824	$ 1,788

Leasehold improvements and Eq_4

Leasehold improvements and Equipment - Schedule of Leasehold Improvements and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Cost	$ 9,785
Accumulated Depreciation	3,934
Property, Plant and Equipment, Net	5,851	$ 6,365
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	4,819
Accumulated Depreciation	1,195
Property, Plant and Equipment, Net	3,624	3,778
Laboratory and office equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	1,409
Accumulated Depreciation	993
Property, Plant and Equipment, Net	416	498
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	133
Accumulated Depreciation	100
Property, Plant and Equipment, Net	33	40
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	3,424
Accumulated Depreciation	1,646
Property, Plant and Equipment, Net	$ 1,778	$ 2,049

Bank indebtedness (Narrative) (

Bank indebtedness (Narrative) (Details) - 12 months ended Dec. 31, 2020	CAD ($)	USD ($)
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate Description	Borrowings under the operating demand line of credit bear interest at the Bank's prime lending rate plus 2%
Line of Credit Facility, Collateral	The credit facility and term loan (see note 9) are secured by a first ranking movable hypothec on all present and future movable property of the Company for an amount of CAD$4,250,000 ($3,338,000) plus 20%, and a 50% guarantee by Export Development Canada, a Canadian Crown corporation export credit agency.
Line Of Credit Facility, Collateral Amount	$ 4,250,000	$ 3,338,000
Line Of Credit Facility, Collateral Percentage	20.00%
Line Of Credit Facility, Guarantee Percentage By Export Development Canada	50.00%
Line of Credit [Member]
Line of Credit Facility [Line Items]
Long-term Line of Credit	$ 250,000	196,000
Corporate Credit Cards [Member]
Line of Credit Facility [Line Items]
Long-term Line of Credit	75,000	59,000
Foreign Exchange Contract [Member]
Line of Credit Facility [Line Items]
Long-term Line of Credit	$ 425,000	$ 334,000

Long-term debt (Narrative) (Det

Long-term debt (Narrative) (Details)	12 Months Ended
	Dec. 31, 2020CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020USD ($)	Aug. 08, 2017CAD ($)	Aug. 08, 2017USD ($)	Jul. 12, 2017CAD ($)	Jul. 12, 2017USD ($)
Debt Instrument [Line Items]
Aggregate principal amount				$ 7,600,000	$ 5,969,000	$ 6,838,000	$ 5,371,000
Term loan facility [Member]
Debt Instrument [Line Items]
Aggregate principal amount	$ 4,000,000		$ 3,140,000
Debt Instrument, Interest Rate Terms	Bank’s prime lending rate plus 2.50%	Bank’s prime lending rate plus 2.50%
Debt Instrument, Periodic Payment	$ 62,000	$ 49,000

Long-term debt - Schedule of te

Long-term debt - Schedule of term loan (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Other Liabilities Disclosure [Abstract]
Term loan facility	$ 732	$ 1,005
Secured loan	0	192
Total debt	732	1,197
Less: current portion	561	727
Total long-term debt	$ 171	$ 470

Long-term debt - Schedule of _2

Long-term debt - Schedule of term loan principal repayments (Details) - Dec. 31, 2020 $ in Thousands, $ in Thousands	CAD ($)	USD ($)
Other Liabilities Disclosure [Abstract]
2020	$ 714	$ 561
2021	$ 218	$ 171

Convertible Debentures (Narrati

Convertible Debentures (Narrative) (Details)	Aug. 08, 2017CAD ($)	Aug. 08, 2017USD ($)	Jul. 12, 2017CAD ($)$ / sharesshares	Jul. 12, 2017USD ($)	Jun. 25, 2020CAD ($)$ / shares	Jun. 25, 2020USD ($)	Jun. 27, 2019CAD ($)	Jun. 27, 2019USD ($)	Dec. 31, 2020CAD ($)shares	Dec. 31, 2020USD ($)shares	Dec. 31, 2019CAD ($)shares	Dec. 31, 2019USD ($)shares	Jun. 25, 2020$ / shares	May 08, 2018$ / shares	Aug. 08, 2017USD ($)	Jul. 12, 2017USD ($)$ / sharesshares
Convertible Debentures [Line Items]
Adjustments to additional paid in capital, convertible debentures converted into common stock | $										$ 103,000
Proceeds from issuance of convertible debentures	$ 762,000	$ 598,000	$ 6,838,000	$ 5,371,000
Aggregate principal amount	7,600,000		6,838,000												$ 5,969,000	$ 5,371,000
Debentures issued, price per debenture	$ 1,000	$ 785	$ 1,000	$ 785
Debt Instrument, interest rate			8.00%													8.00%
Convertible debentures, conversion price | (per share)			$ 1.35		$ 0.50								$ 0.39	$ 0.80		$ 1.06
Convertible debentures, number of shares per instrument			740													740
Gain on extinguishment									$ 547,000	401,000
Accretion expense									398,000	297,000	$ 443,000	$ 334,000
Convertible debentures were converted into common stock, Value									141,000	111,000
Interest accrued									606,000	452,000	606,000	457,000
Interest paid on convertible debentures					$ 309,000	$ 218,000	$ 303,000	$ 229,000			$ 303,000	$ 228,000
Interest paid by issuance of common shares									$ 297,000	$ 234,000
Interest paid by issuance of common shares (Shares)									887,880	887,880	415,179	415,179
Common Stock [Member]
Convertible Debentures [Line Items]
Convertible debentures were converted into common stock, Shares									282,000	282,000
Additional Paid-in Capital [Member]
Convertible Debentures [Line Items]
Adjustments to additional paid in capital, convertible debentures converted into common stock | $										$ 103,000

Convertible Debentures - Schedu

Convertible Debentures - Schedule of Convertible Debt (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Convertible Debt [Abstract]
Face value of the convertible debentures	$ 5,848
Gain on extinguishment	(430)
Transaction costs	(74)
Accretion	117
Convertible Debt	$ 5,461

Convertible Notes (Narrative) (

Convertible Notes (Narrative) (Details)	Oct. 15, 2020USD ($)$ / shares	May 08, 2018USD ($)$ / sharesshares	Oct. 23, 2020USD ($)$ / shares	Dec. 31, 2020CAD ($)shares	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)	Jun. 25, 2020$ / shares	Jun. 25, 2020$ / shares	Aug. 08, 2017CAD ($)	Aug. 08, 2017USD ($)	Jul. 12, 2017CAD ($)$ / shares	Jul. 12, 2017USD ($)$ / shares
Debt Instrument [Line Items]
Stock Issued During Period, Shares, Conversion of Units | shares		320
Subscription Price of Units		$ 10,000
Stock Issued During Period, Value, Conversion of Units		$ 3,200,000
Stock Issued During Period, Value, Conversion of Convertible Securities				$ 141,000	$ 111,000
Warrants Issued During Period, Warrants | shares		7,690
Interest Rate on Convertible Note		6.00%
Debt instrument, face amount									$ 7,600,000	$ 5,969,000	$ 6,838,000	$ 5,371,000
Convertible notes, conversion price | (per share)		$ 0.80					$ 0.50	$ 0.39			$ 1.35	$ 1.06
Sale of Stock, Price Per Share | $ / shares		$ 0.80
Commission Paid to Agents		$ 157,800
Stock Issued During Period, Shares, Issued for Services | shares		243,275
Equity Issuance, Per Share Amount | $ / shares		$ 0.80
Warrants Issued During Period, Value		$ 50,000			44,000
Accretion Expense					539,000	$ 514,000
Financing Interest Expense					96,000	96,000
Interest on convertible notes					29,000
ASU 2014-13, Consolidation (Topic 810) Measuring the Financial Assets and the Financial Liabilities of a Consolidated Collateralized Financing Entity [Policy Text Block]					1,897
Net Proceeds of Units					$ 2,872,000
Convertible debt securities [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares				7,940	7,940
Stock Issued During Period, Value, Conversion of Convertible Securities					$ 5,000
Interest Rate on Convertible Note				6.00%	6.00%
Common stock [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares				282,000	282,000
Net Proceeds of Units					$ 1,460,000
Warrants [Member]
Debt Instrument [Line Items]
Net Proceeds of Units					437,000
6% convertible notes [Member]
Debt Instrument [Line Items]
Transactions Costs of Convertible Notes					111,000
Accretion Expense					231,000	$ 182,000
Net Proceeds of Units					975,000
8% convertible notes [Member]
Debt Instrument [Line Items]
Transactions Costs of Convertible Notes					268,000
Accretion Expense					$ 11
8% convertible notes [Member] | Private Placement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,200,000		$ 557,000
Convertible notes percentage	8.00%		8.00%
Convertible notes, conversion price | $ / shares	$ 0.18		$ 0.18
Payments of debt issuance costs	$ 85,000		$ 39,000
Warrants Issued During Period, Value	$ 482,000		$ 222,800
Exercise price of warrants issued | $ / shares	$ 0.18		$ 0.18

Convertible Notes - Schedule of

Convertible Notes - Schedule of proceeds of equity components based on fair value (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Gross proceeds of units	$ 3,200
Transaction costs of units	328
Net proceeds of units	2,872
Common stock [Member]
Debt Instrument [Line Items]
Gross proceeds of units	1,627
Transaction costs of units	167
Net proceeds of units	1,460
Warrants [Member]
Debt Instrument [Line Items]
Gross proceeds of units	487
Transaction costs of units	50
Net proceeds of units	437
Convertible notes [Member]
Debt Instrument [Line Items]
Gross proceeds of units	1,086
Transaction costs of units	111
Net proceeds of units	$ 975

Convertible Notes - Schedule _2

Convertible Notes - Schedule of Components of the Convertible Notes (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Convertible notes	$ 1,505	$ 1,255
6% convertible notes [Member]
Debt Instrument [Line Items]
Attributed value of net proceeds to convertible notes	975	975
Accretion	511	280
Convertible notes	1,486	$ 1,255
8% convertible notes [Member]
Debt Instrument [Line Items]
Attributed value of net proceeds to convertible notes	1,494
Accretion	11
Convertible notes	$ 1,505

Commitments (Narrative) (Detail

Commitments (Narrative) (Details) € in Thousands	Dec. 31, 2020EUR (€)
Commitments and Contingencies Disclosure [Abstract]
Purchase Obligation	€ 1,911
Payments made in respect to purchase obligation	€ 1,425

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Details)	Feb. 11, 2020CAD ($)$ / sharesshares	Feb. 11, 2020USD ($)shares	May 08, 2018USD ($)$ / sharesshares	Dec. 31, 2020CAD ($)$ / shares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)shares	Dec. 31, 2020USD ($)$ / shares	Feb. 11, 2020$ / shares
Class of Stock [Line Items]
Commission Paid to Agents			$ 157,800
Stock Issued During Period, Shares, Issued for Services | shares			243,275
Equity Issuance, Per Share Amount | $ / shares			$ 0.80
Warrants Issued During Period, Value			$ 50,000		$ 44,000
Fair value of common stock and warrant issued					2,872,000
Proceeds from Issuance Initial Public Offering					5,564,000
Options exercised						$ 21,000
Stock-based compensation					193,000	333,000
Stock options granted to employees and directors [Member]
Class of Stock [Line Items]
Stock-based compensation					156,000	286,000
Stock options granted to consultant [Member]
Class of Stock [Line Items]
Stock-based compensation					37,000	47,000
Unrecognized stock-based compensation [Member]
Class of Stock [Line Items]
Stock-based compensation					180,000	157,000
ASU 2014-13, Consolidation (Topic 810) Measuring the Financial Assets and the Financial Liabilities of a Consolidated Collateralized Financing Entity [Policy Text Block]
Class of Stock [Line Items]
Stock-based compensation						$ 36,000
Public Offering [Member]
Class of Stock [Line Items]
Commission Paid to Agents				$ 763,000			$ 572,000
Stock Issued During Period, Shares, Issued for Services | shares					1,142,190
Equity Issuance, Per Share Amount | (per share)				$ 0.75	$ 0.56
Warrants Issued During Period, Value					$ 125,000
Increase in additional paid in capital					125,000
Fair value of common stock and warrant issued					5,119,000
Number of closing units | shares	16,317,000	16,317,000
Proceeds from Issuance Initial Public Offering	$ 8,158,500	$ 6,137,000
Share Price | (per share)	$ 0.50			$ 0.75			$ 0.56	$ 0.37
Common Stock [Member]
Class of Stock [Line Items]
Fair value of common stock and warrant issued					1,460,000
Number of options exercised | shares						50,000
Common Stock [Member] | Public Offering [Member]
Class of Stock [Line Items]
Fair value of common stock and warrant issued					3,912,000
Warrant [Member]
Class of Stock [Line Items]
Fair value of common stock and warrant issued					437,000
Warrant [Member] | Public Offering [Member]
Class of Stock [Line Items]
Fair value of common stock and warrant issued					1,207,000
Additional Paid-in Capital [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value					$ 0
Proceeds from Stock Options Exercised						$ 21,000
Options exercised						$ 21,000

Capital Stock - Schedule of Sto

Capital Stock - Schedule of Stock by Class (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Common stock, shares authorized	200,000,000	200,000,000
Common stock, par value per share (in dollars per share)	$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized	20,000,000	20,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Common stock, shares, issued	111,429,532	93,942,652
Common Stock, Value, Issued	$ 1	$ 1

Capital Stock - Schedule of pro

Capital Stock - Schedule of proceeds of equity components based on fair value (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Class of Stock [Line Items]
Gross proceeds of units	$ 3,200
Transaction costs of units	328
Net proceeds of units	2,872
Common stock [Member]
Class of Stock [Line Items]
Gross proceeds of units	1,627
Transaction costs of units	167
Net proceeds of units	1,460
Warrants [Member]
Class of Stock [Line Items]
Gross proceeds of units	487
Transaction costs of units	50
Net proceeds of units	437
Public Offering [Member]
Class of Stock [Line Items]
Gross proceeds of units	6,137
Transaction costs of units	1,018
Net proceeds of units	5,119
Public Offering [Member] | Common stock [Member]
Class of Stock [Line Items]
Gross proceeds of units	4,690
Transaction costs of units	778
Net proceeds of units	3,912
Public Offering [Member] | Warrants [Member]
Class of Stock [Line Items]
Gross proceeds of units	1,447
Transaction costs of units	240
Net proceeds of units	$ 1,207

Additional Paid-In Capital (Nar

Additional Paid-In Capital (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 27, 2019	Dec. 31, 2020	Dec. 31, 2019
Schedule of Additional Paid In Capital [Line Items]
Stock based compensation		$ 193	$ 333
Employees and Directors
Schedule of Additional Paid In Capital [Line Items]
Stock based compensation		$ 180
Additional Paid-in Capital [Member]
Schedule of Additional Paid In Capital [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.13	$ 0.40
2016 Stock Option Plan [Member]
Schedule of Additional Paid In Capital [Line Items]
Common stock reserved for issuance		9,347,747
2016 Stock Option Plan [Member] | Additional Paid-in Capital [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock based compensation		$ 193	$ 333
Unrecognized stock-based compensation [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock based compensation		180	157
ASU 2014-13, Consolidation (Topic 810) Measuring the Financial Assets and the Financial Liabilities of a Consolidated Collateralized Financing Entity [Policy Text Block]
Schedule of Additional Paid In Capital [Line Items]
Stock based compensation			$ 36
Deferred Share Units [Member]
Schedule of Additional Paid In Capital [Line Items]
Deferred Share Units Grants in Period	271,740
Salaries, Wages and Officers' Compensation	$ 128
Performance and restricted share units
Schedule of Additional Paid In Capital [Line Items]
Performance and restricted share units issued			53,846

Additional Paid-In Capital - Sc

Additional Paid-In Capital - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Additional Paid in Capital [Abstract]
Exercise price	$ 0.27	$ 0.69
Expected volatility	77.00%	64.00%
Expected life	5 years 7 months 17 days	5 years 7 months 17 days
Risk-free interest rate	0.39%	2.18%
Dividend yield

Additional Paid-In Capital - _2

Additional Paid-In Capital - Schedule of Stock Option Activity to Employees and Directors (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of Additional Paid In Capital [Line Items]
Outstanding, Number, Beginning of Period
Options, Outstanding, Weighted Average Exercise Price, Beginning of Period
Exercise price	$ (0.27)	$ (0.69)
Options, Outstanding, Number, End of Period	5,179,818
Options, Outstanding, Weighted Average Exercise Price, End of Period	$ 0.57
Share-based Payment Arrangement, Option [Member]
Schedule of Additional Paid In Capital [Line Items]
Outstanding, Number, Beginning of Period	3,464,818	3,854,818
Options, Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.68	$ 0.68
Options, Grants in Period	1,390,000	100,000
Options, Grants in Period, Weighted Average Exercise Price	$ 0.27	$ 0.69
Options, Forfeitures in Period		(37,500)
Options, Forfeitures in Period, Weighted Average Exercise Price		$ (0.66)
Options, Expirations in Period	(225,000)	(402,500)
Options, Expirations in Period, Weighted Average Exercise Price	$ (0.61)	$ (0.67)
Options, Exercises in Period		(50,000)
Exercise price		$ (0.41)
Options, Outstanding, Number, End of Period	4,629,818	3,464,818
Options, Outstanding, Weighted Average Exercise Price, End of Period	$ 0.56	$ 0.68

Additional Paid-In Capital - _3

Additional Paid-In Capital - Schedule of Stock Option Activity to Consultants (Details)	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Schedule of Additional Paid In Capital [Line Items]
Options, Outstanding, Number, End of Period | shares	5,179,818
Options, Outstanding, Weighted Average Exercise Price, End of Period | $ / shares	$ 0.57
Consultant's stock options [Member]
Schedule of Additional Paid In Capital [Line Items]
Outstanding, Number, Beginning of Period | shares	550,000
Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ / shares	$ 0.72
Options, Outstanding, Number, End of Period | shares	550,000
Options, Outstanding, Weighted Average Exercise Price, End of Period | $ / shares	$ 0.72

Additional Paid-In Capital - _4

Additional Paid-In Capital - Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of Additional Paid In Capital [Line Items]
Options, Exercises in Period, Weighted Average Exercise Price	$ 0.27	$ 0.69
Options, Outstanding, Number, Beginning of Period	5,179,818
Outstanding Options, Weighted Average Remaining Contractual Term	6 years 4 months 13 days
Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.57
Options, Outstanding, Intrinsic Value, Beginning of Period	$ 0
Options, Exercisable, Number, Beginning of Period	3,764,818
Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	$ 0.69
Options, Exercisable, Intrinsic Value, Beginning of Period	$ 0
Range 1 [Member]
Schedule of Additional Paid In Capital [Line Items]
Options, Exercises in Period, Weighted Average Exercise Price	$ 0.27
Options, Outstanding, Number, Beginning of Period	1,390,000
Outstanding Options, Weighted Average Remaining Contractual Term	2 years 7 months 28 days
Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.07
Options, Exercisable, Number, Beginning of Period	0
Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	$ 0
Range 2 [Member]
Schedule of Additional Paid In Capital [Line Items]
Options, Exercises in Period, Weighted Average Exercise Price	$ 0.41
Options, Outstanding, Number, Beginning of Period	275,000
Outstanding Options, Weighted Average Remaining Contractual Term	3 days
Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.02
Options, Exercisable, Number, Beginning of Period	275,000
Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	$ 0.03
Range 3 [Member]
Schedule of Additional Paid In Capital [Line Items]
Options, Exercises in Period, Weighted Average Exercise Price	$ 0.58
Options, Outstanding, Number, Beginning of Period	600,000
Outstanding Options, Weighted Average Remaining Contractual Term	6 months 7 days
Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.07
Options, Exercisable, Number, Beginning of Period	600,000
Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	$ 0.09
Range 4 [Member]
Schedule of Additional Paid In Capital [Line Items]
Options, Exercises in Period, Weighted Average Exercise Price	$ 0.66
Options, Outstanding, Number, Beginning of Period	200,000
Outstanding Options, Weighted Average Remaining Contractual Term	3 months 10 days
Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.03
Options, Exercisable, Number, Beginning of Period	200,000
Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	$ 0.04
Range 5 [Member]
Schedule of Additional Paid In Capital [Line Items]
Options, Exercises in Period, Weighted Average Exercise Price	$ 0.69
Options, Outstanding, Number, Beginning of Period	100,000
Outstanding Options, Weighted Average Remaining Contractual Term	1 month 28 days
Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.01
Options, Exercisable, Number, Beginning of Period	75,000
Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	$ 0.01
Range 6 [Member]
Schedule of Additional Paid In Capital [Line Items]
Options, Exercises in Period, Weighted Average Exercise Price	$ 0.70
Options, Outstanding, Number, Beginning of Period	475,000
Outstanding Options, Weighted Average Remaining Contractual Term	2 months 4 days
Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.06
Options, Exercisable, Number, Beginning of Period	475,000
Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	$ 0.09
Range 7 [Member]
Schedule of Additional Paid In Capital [Line Items]
Options, Exercises in Period, Weighted Average Exercise Price	$ 0.73
Options, Outstanding, Number, Beginning of Period	525,000
Outstanding Options, Weighted Average Remaining Contractual Term	6 months 10 days
Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.07
Options, Exercisable, Number, Beginning of Period	525,000
Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	$ 0.10
Range 8 [Member]
Schedule of Additional Paid In Capital [Line Items]
Options, Exercises in Period, Weighted Average Exercise Price	$ 0.76
Options, Outstanding, Number, Beginning of Period	905,000
Outstanding Options, Weighted Average Remaining Contractual Term	1 year 3 months 7 days
Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.13
Options, Exercisable, Number, Beginning of Period	905,000
Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	$ 0.18
Range 9 [Member]
Schedule of Additional Paid In Capital [Line Items]
Options, Exercises in Period, Weighted Average Exercise Price	$ 0.77
Options, Outstanding, Number, Beginning of Period	359,818
Outstanding Options, Weighted Average Remaining Contractual Term	5 months 15 days
Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.05
Options, Exercisable, Number, Beginning of Period	359,818
Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	$ 0.07
Range 10 [Member]
Schedule of Additional Paid In Capital [Line Items]
Options, Exercises in Period, Weighted Average Exercise Price	$ 0.78
Options, Outstanding, Number, Beginning of Period	100,000
Outstanding Options, Weighted Average Remaining Contractual Term	3 days
Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.02
Options, Exercisable, Number, Beginning of Period	100,000
Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	$ 0.02
Range 11 [Member]
Schedule of Additional Paid In Capital [Line Items]
Options, Exercises in Period, Weighted Average Exercise Price	$ 0.89
Options, Outstanding, Number, Beginning of Period	250,000
Outstanding Options, Weighted Average Remaining Contractual Term	3 months 14 days
Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.04
Options, Exercisable, Number, Beginning of Period	250,000
Options, Exercisable, Weighted Average Exercise Price, Beginning of Period	$ 0.06

Additional Paid-In Capital - _5

Additional Paid-In Capital - Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details)	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Additional Paid in Capital [Abstract]
Class of Warrant or Right, Outstanding, Beginning of Period | shares	12,904,397
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ / shares	$ 0.9470
Class Of Warrant Or Right Granted | shares	18,163,990
Class Of Warrant Or Right Granted In Period Weighted Average Exercise Price | $ / shares	$ 0.5453
Class of Warrant or Right, Outstanding, End of Period | shares	31,068,387
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price, End of Period | $ / shares	$ 0.7125

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	$ 2,802	$ 2,486
Expiring in 2026 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	8
Expiring in 2027 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	10
Expiring in 2028 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	177
Expiring in 2029 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	155
Expiring in 2030 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	132
Expiring in 2031 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	141
Expiring in 2032 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	176
Expiring in 2033 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	117
Expiring in 2034 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	89
Expiring in 2035 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	104
Expiring in 2036 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	144
Expiring in 2037 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	275
Expiring in 2038 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	594
Expiring in 2039 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	359
Expiring in 2040 [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	298
Undeducted research and development expenses with no expiration date [Member]
Tax Credit Carryforward [Line Items]
Non-refundable tax credits	15,302	14,282
Canadian federal [Member]
Tax Credit Carryforward [Line Items]
Operating Loss Carryforwards	31,673	23,101
Provincial [Member]
Tax Credit Carryforward [Line Items]
Operating Loss Carryforwards	$ 33,905	$ 25,265

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Statutory income taxes	$ (1,716)	$ (2,398)
Net operating losses for which no tax benefits have been recorded	1,048	1,189
Deficiency of depreciation over capital cost allowance	(28)	(178)
Non-deductible expenses	455	667
Undeducted research and development expenses	409	820
Investment tax credit	(168)	(100)
Income tax expense (benefit), total	$ 0	$ 0

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Leasehold improvements and equipment	$ 445	$ 440
Net operating losses carryforward	8,684	6,396
Undeducted research and development expenses	3,534	2,903
Non-refundable tax credits carryforward	2,506	2,082
Deferred Tax Assets, Gross	15,169	11,821
Valuation allowance	(15,169)	(11,821)
Deferred Tax Assets, Net	$ 0	$ 0

Revenues (Narrative) (Details)

Revenues (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Revenue from Contract with Customer [Abstract]
Transaction price allocated to the remaining performance obligation	$ 1,425
Research and development milestone payments	$ 2,558
Percentages of milestone payments recognized in next three years	100.00%
Commercial sales milestone payments	$ 433

Revenues - Schedule of Disaggre

Revenues - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Total revenues	$ 1,544	$ 742
Research and development agreements [Member]
Disaggregation of Revenue [Line Items]
Total revenues	562	742
Licensing Agreements [Member]
Disaggregation of Revenue [Line Items]
Total revenues	$ 982	$ 0

Revenues - Schedule of Revenue,

Revenues - Schedule of Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenues	$ 1,544	$ 742
Product and services transferred at point in time [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenues	1,185	372
Products and services transferred over time [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenues	$ 359	$ 370

Revenues - Schedule of Revenue

Revenues - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 1,544	$ 742
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenues	795	534
Canada [Member]
Disaggregation of Revenue [Line Items]
Revenues	708	208
United States [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 41	$ 0

Statement of Cash Flows Infor_3

Statement of Cash Flows Information - Schedule of Cash Flow, Supplemental Disclosures (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Additional Cash Flow Information:
Interest paid	$ 441	$ 465

Leases (Narrative) (Details)

Leases (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Leases [Line Items]
Operating lease expense	$ 87
Cash outflows from operating leases	91
Variable lease expense	$ 64
Weighted average remaining lease term	5 years 2 months 12 days
Weighted average discount rate for operating leases	10.00%
Finance lease	$ 2
Weighted average remaining lease term for finance lease	4 years
Weighted average discount rate for finance lease	6.43%

Leases - Schedule of reconciles

Leases - Schedule of reconciles undiscounted cash flows for operating leases (Details) $ in Thousands	Dec. 31, 2020USD ($)
Operating Leases
2021	$ 155
2022	159
2023	161
2024	164
2025	164
Thereafter	28
Total undiscounted lease payments	831
Less: Interest	208
Present value of lease liabilities	$ 623

Leases - Schedule of operating

Leases - Schedule of operating lease liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Current portion of operating lease liability	$ 141	$ 137
Operating lease liability	$ 482	$ 555

Leases - Schedule of reconcil_2

Leases - Schedule of reconciles undiscounted cash flows for finance leases (Details) $ in Thousands	Dec. 31, 2020USD ($)
Leases [Abstract]
2021	$ 32
2022	32
2023	32
2024	29
Total undiscounted lease payments	125
Less: Interest	16
Present value of lease liabilities	$ 109

Leases - Schedule of Finance le

Leases - Schedule of Finance leases liabilities (Details) $ in Thousands	Dec. 31, 2020USD ($)
Leases [Abstract]
Current portion of finance lease liability	$ 25
Finance lease liability	$ 84

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Options granted to Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	$ 20	$ 67
Options granted to President and Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	51	50
Options Granted To Vice-President, Research and Development [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	10	29
Options granted to Vice- President, Business and Corporate Development [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	10	29
Options Granted To Vice President, Operations [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	30	36
Director fees [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	$ 233	$ 231

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details)

Jan. 11, 2021$ / sharesshares

Jan. 01, 2021CAD ($)shares

Mar. 15, 2021USD ($)shares

Dec. 31, 2020CAD ($)$ / shares

Dec. 31, 2019$ / shares

Mar. 15, 2021CAD ($)$ / shares

Mar. 15, 2021USD ($)

Jan. 01, 2021USD ($)

Dec. 31, 2020USD ($)

Aug. 08, 2017CAD ($)

Aug. 08, 2017USD ($)

Jul. 12, 2017CAD ($)

Jul. 12, 2017USD ($)

Subsequent Event [Line Items]

Options, Exercises in Period, Weighted Average Exercise Price | $ / shares

$ 0.27

$ 0.69

Convertible Debt

$ 5,461,000

Debt instrument, face amount

$ 7,600,000

$ 5,969,000

$ 6,838,000

$ 5,371,000

Term loan facility [Member]

Subsequent Event [Line Items]

Debt instrument, face amount

$ 4,000,000

$ 3,140,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Convertible Debt

$ 301,000

$ 236,000

Number of convertible debentures converted into common shares at the option of holders | shares

602,000

Subsequent Event [Member] | Atai Life Sciences ("atai") | Term loan facility [Member]

Subsequent Event [Line Items]

Debt instrument, face amount

$ 2,000,000

Debt instrument stated interest rate

8.00%

8.00%

Maximum proceeds from subscription of additonal units

$ 3,000,000

Additional advance subject to certain conditions

$ 500,000

Line of credit facility, maximum borrowing capacity for repayment of outstanding loan

$ 800,000

$ 628,000

Subsequent Event [Member] | Strategic Development Agreement | Atai Life Sciences ("atai")

Subsequent Event [Line Items]

Ownership interest acquired by equity investment

25.00%

25.00%

Debt instrument, face amount

$ 2,000,000

Number of shares issued | shares

37,300,000

Number of warrants issued | shares

22,380,000

Proceeds from issuance of common stock and warrants

$ 12,346,300

Exercise price of warrants | $ / shares

$ 0.35

Warrants and Rights Outstanding, Term

3 years

3 years

Maximum rights to subscribe additional units | shares

130,000,000

Maximum term for rights to subscribe additional units

3 years

Right to subscribe additional units, description

Each additional unit will be comprised of (i) one share of common stock and (ii) one half of one warrant. The price for the additional units will be (i) until the date which is 12 months following the closing, $0.331 (subject to certain exceptions), and (ii) following the date which is 12 months following the closing, the lower of (A) a 20% premium to the market price on the date of purchase, and (B) $0.50 if purchased in the second year following closing and $0.75 if purchased in third year following closing. Each additional warrant will entitle atai, for a period of three years from the date of issuance, to purchase one share at the lesser of either (i) a 20% premium to the price of the corresponding additional share, or (ii) the price per share under which shares of the Company are issued under convertible instruments that were outstanding on February 16, 2021, the date on which the parties entered into a non-binding letter of intent to enter into a definitive securities purchase agreement, provided that atai may not exercise additional warrants to purchase more than the lesser of (x) 44,000,000 common shares of the Company, and (y) the number of common shares issued by the Company under outstanding convertibles. Under the securities purchase agreement, the Company also granted atai a pro-rata equity participation right for any issuances of new securities, subject to certain exceptions. Following the initial closing, atai will hold approximately 25% (approximately 35% on a partially diluted basis) of the issued and outstanding shares and therefore become a new "Control Person" of the Company as such term is defined under the policies of the Exchange. Based on the number of issued and outstanding shares and outstanding convertible instruments on the date hereof, assuming the full exercise of its option to acquire the additional units and exercise of the initial warrants and additional warrants, atai would hold approximately 60% (approximately 60% on a partially diluted basis) of the issued and outstanding Shares.

Subsequent Event [Member] | 2016 Stock Option Plan

Subsequent Event [Line Items]

Options, Grants in Period, Gross | shares

150,000

Options, Exercises in Period, Weighted Average Exercise Price | $ / shares

$ 0.27

Award Vesting Period

2 years

Award Vesting Rights, Percentage

25.00%

Expiration Period

10 years